Abstract PD10-11: Keyriched-1- A Prospective, Multicenter, Open Label, Neoadjuvant Phase Ii Single Arm Study with Pembrolizumab in Combination with Dual Anti-Her2 Blockade with Trastuzumab and Pertuzumab in Early Breast Cancer Patients with Molecular HER2-enriched Intrinsic Subtype